Last reviewed · How we verify

NCT06984887: TB

Evaluation of New TB Diagnostic Tests (NATs) in Pakistan

ENROLLING BY INVITATION NA Last updated 2 January 2026
What this trial tests

NA trial testing Diagnostic procedures in Tuberculosis Diagnosis in 6,100 participants. Enrolling by invitation.

Timeline
19 December 2025
Primary endpoint
31 May 2026
30 August 2026

Quick facts

Lead sponsorMercy Corps Pakistan
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment6,100
Start date19 December 2025
Primary completion31 May 2026
Estimated completion30 August 2026
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Mercy Corps Pakistan

Who can join

12 and older, any sex, with Tuberculosis Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to test new diagnostic methods for tuberculosis (TB) testing as compared to the existing Xpert MTB/Rif Ultra testing approach. The research questions that will be addressed by this study include: * What are the sensitivity and specificity of the new diagnostic tests Pluslife MTBC and Ustar PortNAT for tuberculosis and how do these compare to Xpert Ultra? * How does the new diagnostic method compare to Xpert Ultra in terms of implementation feasibility, cost and turnaround time? * What are the logistical and technical advantages and challenges associated with implementing the new diagnostic method compared to Xpert Ultra? * What are the perceptions of healthcare providers as well as sample provider regarding the usability, feasibility and convenience of use of the new sample collection method compared to existing methods?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Diagnostic procedures

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06984887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing